Paul Hastings Advises ACELYRIN in Alumis Merger

Paul Hastings LLP advised ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, on its merger agreement with Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases.

The Paul Hastings team was led by global co-chair of Mergers & Acquisitions Eduardo Gallardo and partners Sean Donahue and Andrew Goodman.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations. For more information, visit www.paulhastings.com.